Search RHCG Website
Select your language

COVID Digits: Advice for Referrers

exp date isn't null, but text field is

During the COVID-19 pandemic, there has been an emergence of a chilblains-like phenomenon affecting fingers and toes. This is poorly understood and not always associated with positive coronavirus virology (antibodies or blood/respiratory PCR). Often children have had no typical symptoms of COVID-19 infection. It tends to affect younger people, can occur a few weeks after COVID-19 infection, or late in the disease course. Children and young people may present with swollen toes and/or fingers, which may be erythematous, purpuric or violaceous, associated with cutaneous manifestations such as macules, papules, desquamation and ulceration. The lesions may be pruritic or painful.

The majority of children and young people presenting in this way have a benign course and the lesions resolve without intervention within one month. Therefore, not all patients will require a referral and if the patient presents very early, or is already improving, can have expectant management.

The differential diagnosis of dactylitis includes infection (cellulitis, osteomyelitis), sickle-cell anaemia, gout, sarcoidosis and spondyloarthropathy e.g. psoriatic arthritis. The presentation with cutaneous lesions may, in a small number of children and young people, represent an underlying systemic connective tissue disease or vasculitic process such as systemic lupus erythematous or cryoglobulinaemia. 

In all children and young people presenting with erythematous and/or swollen digits, a full history and systematic examination, including joint assessment, should be carried out.

If the patient is systemically unwell, consider referral to hospital under the acute paediatric medical team/rheumatology for further investigation and management.

Information to Include - History

Does the child complain of:

  • Joint pain?
  • Joint swelling?
  • Colour changes of joints?
  • Rashes?

  • What is the duration of symptoms?
  • What is the effect of cold exposure on symptoms?
  • Are there any features of connective tissue disease e.g. weight loss, fever, oral ulcers, arthritis, abdominal pain, haematuria?
  • COVID history – patient and family members
  • Family history – arthritis, psoriasis, Inflammatory Bowel Disease
Information to Include - Examination
  • Is there joint restriction, swelling, erythema, heat?
  • Presence of rashes or livido
  • Details of a general systematic examination
Suggestions for investigations whilst waiting for outpatient appointment

In the absence of an obvious alternative diagnosis such as cellulitis or injury, the following investigations should be performed, if possible (and included in the referral letter):

  • Bloods including FBC, ESR, electrolytes, LFTs, CRP, ANA (please note that we would not expect very young children to have bloods obtained at their GP practice - this can be done on paediatric review)
  • Vital signs including blood pressure
  • Send in a clinical photograph, or series of photographs if possible
  • Testing for COVID-19 (via blood or throat/nose swab) is not required unless the patient has other features of COVID-19
Suggestions for management whilst waiting for outpatient appointment

If there are other systemic features such as fever, malaise, joint symptoms or signs (arthralgia, swelling, erythema, heat, restricted movement, widespread rash) – discuss with paediatric rheumatology.

If the child or young person is otherwise systemically well, give advice to keep the hands and feet warm and covered and avoid cold/damp exposure. Symptomatic management such as simple analgesia and anti-histamines for pruritis should be provided. In the majority of cases with mild symptoms, reassurance is all that is required.

If needed, consider a short course of topical steroids, such as:

  • Betnovate ointment once nightly for 7-10 days.
  • Mometasone 0.1% ointment once nightly for 14 nights.
  • Clobetasol propionate 0.05% ointment twice daily for 7 days.

If topical steroids have already been trialled without success, consider a short course of oral prednisolone, 1mg/kg once daily for 7 days.

In the absence of any other concerning features, give worsening advice and advise the patient/carer to seek further review if ongoing symptoms at 6 weeks. At this stage, a referral to paediatric rheumatology is warranted.

Useful resources for Health Professionals

Massey PR, Jones KM. Going viral: A brief history of Chilblain-like skin lesions (“COVID toes”) amidst the COVID-19 pandemic. Semin Oncol. 2020 Oct; 47(5): 330–334.

Baeck M, Herman A. COVID toes: where do we stand with the current evidence? Int J Infect Dis. 2021 Jan; 102: 53–55.

Carrascosa JM, Morillas V, Biela I, Munera-Campos M. Cutaneous Manifestations in the Context of SARS-CoV-2 infection (COVID-19). Actas Dermosifiliogr. 2020 Nov; 111(9): 734-742.

Andina D, Noguera-Morel L, Bascuas-Arribas M, Gaitero-Tristan J, Alonso-Cadenas JA, Escalada-Pellitero S, Hernandez-Martin A, de la Torre-Espi M, Colmenero I, Torrerlo A. Chilblains in children in the setting of COVID‐19 pandemic. Pediatr Dermatol. 2020 May;37(3):406-411.

Ladha MA , Luca N , Constantinescu C , Naert K, Ramien ML. Approach to Chilblains During the COVID-19 Pandemic. J Cutan Med Surg. Sep/Oct 2020;24(5):504-517

Editorial Information

Last reviewed: 01 June 2021

Next review: 30 June 2024

Author(s): Dr Jaclyn Keightley, Consultant Paediatrician with an interest in Rheumatology Royal Hospital for Children, Glasgow

Co-Author(s): Adapted from ‘Covid toes’: guideline for investigation and management of acutely swollen and erythematous fingers and toes, NHS Lothian, Dr K Macgill and Dr M Brennan.